Avelumab plus axitinib significantly improve progression-free survival in untreated renal cell carcinoma
byEuropean Society for Medical OncologyCredit: CC0 Public DomainA combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improv
Updated on: December 18,2023
19

Avelumab plus axitinib significantly improve progression-free survival in untreated renal cell carcinoma
byEuropean Society for Medical OncologyCredit: CC0 Public DomainA combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improv
Updated on:December 18,2023
19
